Searched for
HIKMA PHARMACEUTICALS
Stocks in the news: HUL, Sun Pharma, Adani Enterprises, IndiGo, Paytm and LupinAdani Enterprises has acquired 100 percent stake in Alluvial Mineral Resources, from Adani Infra (India). Alluvial Mineral Resources is eng...- Lupin appoints Spiro Gavaris as president of US generics bizSpiro, who had most recently served as president of Specialty Generics business at Mallinckrodt Pharmaceuticals and the president of US Inj...
- Stocks in the news: Biocon, NMDC, Brigade Enterprises, PB Fintech, SpiceJet and NDTVRajesh Exports, AVG Logistics, Shahlon Silk Industries, MRC Agrotech, Lee & Nee Softwares, Milton Industries and Destiny Logistics & Infra ...
- Hold Gland Pharma, target price Rs 2100: Axis SecuritiesGland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 31075.06 Crore) operating in Pharmaceut...
- Glenmark bets on respiratory drug, licensing deals to improve businessGlenmark had gross debt of ₹3,765 crore as of June 30, 2022. The company over the years accumulated debt to fund its innovation-led R&D and...
- Glenmark's partner Hikma launches specialty drug Ryaltris in USRyaltris is the only fixed-dose combination of olopatadine hydrochloride and mometasone furoate approved by the USFDA for the treatment of ...
- Glenmark gets USFDA nod for nasal spray to treat seasonal allergic rhinitisGlenmark Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray...
- Buy Lupin, target price Rs 1150: Emkay GlobalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 42717.22 Crore) operating in Pharmaceuticals s...
- Glenmark gets marketing approval for Ryaltris in 13 EU, UK countriesSales of the nasal spray continue to progress well in Australia, South Africa, Ukraine and Uzbekistan, it said adding the company has also ...
- Glenmark Pharma to launch its nasal spray Ryaltris in EUThe drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and wate...
- Sun Pharma bullish on specialty biz, looks to expand the segment to new geographiesSharing information with shareholders, Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said the company's strategy of develo...
- Sun Pharma, Hikma ink exclusive pact for plaque psoriasis drug for MENA regionUnder the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA...
- Market Movers: RITES falls as OFS sails, Axis Bank gains; buy signals in 25 stocksThe BSE flagship shed 143 points to 39,745 while Nifty dipped 45 points to 11,633.
- Baxter emerges as frontrunner to buy KKR-backed Gland Pharma for $1.1-1.2 billionHyderabad-headquartered Gland is a leading contract manufacturers of injectables, supplying to pharma majors in India and US like Dr Reddy’...
- Sun Pharma against use of its drug for lethal injection in USAccording to a media report, the Arkansas purchased three drugs, including one of Sun Pharma, which were enough to perform eight executions.
- Sun Pharma tanks nearly 9% in two sessions on USFDA import alertShares of Sun Pharma continued to remain under pressure for second straight session after the USFDA issued an Import Alert to its plant.
- Sun Pharma slumps over 6% on USFDA import alert; doxycycline prices fallRanjit Kapadia an analyst at Centrum Broking doesn’t see more than 4-5 per cent revenue hit for the company due to import alert.
- Mylan’s Agila Specialties deal faces riders from US watchdogUS-based generic giant Mylan Inc’s $1.85-billion bid to acquire Indian drugmaker Agila Specialties now faces fresh riders, this time from i...
- Sun Pharma shares gain on strong guidance for doxycyclineSun Pharmaceutical went up 1% after a competitor raised its revenue guidance, citing strong sale of a generic antibiotic also sold by Sun P...
- Jordan's Hikma in talks to buy 30% in Unimark RemediesJordan-based Hikma Pharmaceuticals is in negotiations to buy 30% stake in Mumbai-based Unimark Remedies, two people familiar with the matte...
Load More
